Literature DB >> 671591

Postoperative management of patients with pheochromocytoma.

S M Bergman, H F Sears, N Javadpour, H R Keiser.   

Abstract

The optimal preoperative and postoperative management of patients with pheochromocytoma demands a multidisciplinary approach. We report on 5 recent patients to illustrate the large volumes of fluid needed in the early postoperative period. This large fluid requirement is owing to a combination of a change in vascular compliance after excision of a pheochromocytoma, the residual effects of specific preoperative medications (phenoxybenzamine and alpha-methyl-p-tyrosine) and the loss of fluid into the retroperitoneal compartment (third space) produced by extensive dissection. It takes 3 half-lives (36 hours) to dissipate the effects of phenoxybenzamine and alpha-methyl-p-tyrosine, which corresponds to the time in which these patients require large volumes of intravenous fluids.

Entities:  

Mesh:

Year:  1978        PMID: 671591     DOI: 10.1016/s0022-5347(17)57063-9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  The management of the patient with catecholamine excess.

Authors:  M H Wheeler; M J Chare; T R Austin; J H Lazarus
Journal:  World J Surg       Date:  1982-11       Impact factor: 3.352

2.  Pheochromocytoma - update on disease management.

Authors:  Roland Därr; Jacques W M Lenders; Lorenz C Hofbauer; Bernd Naumann; Stefan R Bornstein; Graeme Eisenhofer
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

Review 3.  alpha-Methyl-p-tyrosine: a review of its pharmacology and clinical use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-02       Impact factor: 9.546

4.  Surgical management of pheochromocytoma with the use of metyrosine.

Authors:  R R Perry; H R Keiser; J A Norton; R T Wall; C N Robertson; W Travis; H I Pass; M M Walther; W M Linehan
Journal:  Ann Surg       Date:  1990-11       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.